Recent Advances in the Management of Dyslipidemia: A Systematic Review

Cureus, Journal Year: 2025, Volume and Issue: unknown

Published: March 23, 2025

Dyslipidemia refers to abnormal levels of lipids in the bloodstream, typically exhibiting an increased pattern. Total cholesterol, high-density lipoprotein-cholesterol (HDL-C), low-density (LDL-C), and triglycerides (TGs) are all contributing factors this disorder. This leads risk atherosclerosis cardiovascular diseases, such as coronary artery disease, which elevates likelihood morbidity. can be managed via use numerous classes drugs treatments. The conventional pharmacological agents comprising 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, selective cholesterol absorption proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i), bile acid sequestrants, monoclonal antibodies, nutritional supplementation, synthesis absorption, promoters LDL-C excretion, also discussed. Furthermore, treatment dyslipidemia may elicit a variety adverse side effects that detrimental quality life user. These include muscle pain, weakness, liver enzyme elevations, hyperglycemia. systematic review further analyzes actions novel lipid-lowering adenosine triphosphate-citrate lyase (ACLi), peroxisome proliferator-activated receptor alpha (PPARα) modulators, cholesteryl ester transfer protein (CETPi), antisense oligonucleotides (ASO), angiopoietin-like 3 (ANGPTL3i) well their efficacy treating while sparing user potentially severe effects. Compared existing treatments, therapies have shown significantly greater effectiveness managing dyslipidemia-related lipid profiles exhibit fewer systemic Some recent discussed alternative treatments offer patients promising improved tolerability. Preferred Reporting Items for Systematic Reviews Meta-Analyses (PRISMA) guidelines were followed ensure robust transparent search process, aiming minimize bias maximize retrieval pertinent studies review. Thus, provides overview current dyslipidemia, describing efficacy, mechanism action, safety, As experimental investigations clinical research progress, there is possibility combination newly tested medications traditional ones emerge option future.

Language: Английский

---

Inflammatory cytokines and specific factors influencing lung cancer progression

Cancer Pathogenesis and Therapy, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Language: Английский

---

The functional significance of vascular DNA hypermethylation in atherosclerosis: a historical perspective

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: April 15, 2025

A decade ago, independent mechanistic and descriptive epigenomics data demonstrated for the first time that vascular DNA hypermethylation is a landmark of causal factor in human murine atherosclerosis. Since then, flurry converging evidence has assigned prominent role to across natural history cardiovascular disease (CVD), from exposure risk factors, onset progression atheroma. induced by mediates metabolic outcomes high-fat diets CVD risk-enhancing lipids several models. Early-stage atheroma hypermethylated compared normal adjacent tissue, trend amplified as progresses. That resulted strong interest epigenetic drugs CVD. Crucially, methylation inhibitor azacytidine been singled out potent guardian contractile, anti-atherogenic phenotype smooth muscle cells (SMC). Those findings are gaining relevance, antiatherogenic effects anticancer decitabine fit into recently revived hypothesis SMC-driven cancer-like mass. Finally, this 10-year anniversary marked report nanoparticles loaded with methyltransferase drug anti-inflammatory inhibit Exciting work lies ahead assess whether practical effective target prevent or cure

Language: Английский

---

Association between soluble suppression of tumorigenicity 2 and risk and severity of coronary artery disease: a case control study

BMC Cardiovascular Disorders, Journal Year: 2025, Volume and Issue: 25(1)

Published: April 28, 2025

Language: Английский

---